Guided injections for AAV gene transfer to muscle
US10842886B2 · kind B2 · utility
0Cited by
6References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 9, 2015 |
| Grant date | Nov 24, 2020 |
| Priority date | — |
| Expiry date | Oct 9, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/025
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure relates to methods for treating subjects with musculoskeletal diseases or with muscle wasting not associated with a musculoskeletal disease by gene transfer with recombinant adeno-associated viruses (rAAV) encoding myostatin inhibitors such as follistatin-344. The rAAV are administered prior to development of diffuse muscle fibrosis in a subject, or the rAAV administration avoids regions of muscle fibrosis in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.